Who are Biological vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comirnaty, Prevnar 20, RECOMBIVAX HB™, Recombinant Human Papillomavirus Nonavalent Vaccine, Recombinant influenza hemagglutinin, IPV at 14 and fIPV at 22 weeks, RotaTeq.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/biological-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Biological vaccine — Competitive Intelligence Brief

Biological vaccine (Biological vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vaccine. Area: Immunology.

phase 3 Vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

Biological vaccine (Biological vaccine) — Inmunotek S.L.. A biological vaccine that stimulates the immune system to recognize and attack disease-causing pathogens or abnormal cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Biological vaccine TARGET	Biological vaccine	Inmunotek S.L.	phase 3	Vaccine
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
RECOMBIVAX HB™	RECOMBIVAX HB™	Merck Sharp & Dohme LLC	marketed	Recombinant vaccine	Hepatitis B surface antigen (HBsAg)
Recombinant Human Papillomavirus Nonavalent Vaccine	Recombinant Human Papillomavirus Nonavalent Vaccine	National Cancer Institute (NCI)	marketed	Recombinant vaccine	Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58
Recombinant influenza hemagglutinin	Recombinant influenza hemagglutinin	Vaxine Pty Ltd	marketed	Recombinant protein vaccine	Influenza hemagglutinin
IPV at 14 and fIPV at 22 weeks, RotaTeq	IPV at 14 and fIPV at 22 weeks, RotaTeq	Centers for Disease Control and Prevention	marketed	vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Vaccine class)

GlaxoSmithKline · 16 drugs in this class
Sanofi Pasteur, a Sanofi Company · 12 drugs in this class
Pfizer · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Henogen · 3 drugs in this class
Pfizer Inc. · 2 drugs in this class
Sanofi · 2 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 2 drugs in this class
BioNTech · 2 drugs in this class
Merck Sharp & Dohme LLC · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Biological vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/biological-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab